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Abstract
The chapter examines the use of stem cells in ophthalmological pathologies 
affecting both the anterior and posterior segments. The authors review the clini-
cal trials that have most contributed to defining the role and potential of stem cell 
regenerative therapy in corneal and retinal pathology. The results described in the 
scientific literature are analyzed and commented, without neglecting the possible 
side effects related to the use of this therapy. Within the anterior segment, the 
greatest efforts were made to study the possible uses of limbal epithelial stem cells 
(LESCs). They were the first stem cells to be discovered at the level of the anterior 
segment and currently the only ones involved in clinical practice with satisfactory 
results. At this juncture there have been significant successes in the treatment of 
corneal stem cell deficiency and of corneal scars. The chapter later investigates 
the possible applications of stem cell therapy in degenerative retinal diseases, with 
particular reference to retinitis pigmentosa, Stargardt’s disease, and age-related 
macular degeneration. It then describes how the use of cell therapies, in particular 
those that use ADSC, can contribute, through various methods, to the containment 
of the evolution of retinal degenerative diseases. These mechanisms cover various 
biological aspects and can be summarized as follows: neurotrophism, oxidation, 
vascular changes, apoptosis, inflammation, or immunology. The ophthalmological 
modalities of the cell graft and what is the ideal approach for an ophthalmological 
cellular surgery are later on described. Finally, the technique used by the author and 
the possible outcomes in the course of degenerative retinopathy are described.
Keywords: ophthalmology, stem cells, regenerative medicine, degenerative diseases
1. Introduction
Regenerative medicine has been a major topic in the last few decades. The use of 
stem cells has opened up new perspectives in the therapeutic approach to many dif-
ferent diseases. Even in the ophthalmological field, the use of stem cells has allowed 
an improvement in the clinical outcome of different pathologies such as limbal stem 
cell deficiency, corneal scarring, retinitis pigmentosa, Stargardt’s disease, age-
related macular degeneration, and retinal atrophy following various vascular condi-
tions. Many of these pathologies have always been considered untreatable, leading 
to a progressive sight loss; the arrival of stem cell therapy has led to an entirely new 
clinical and therapeutic approach to these conditions. Different types of stem cells 
have been tested as a solution for tissue repair in the different ocular structures. 
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As for the anterior segment, the most used cells are limbal epithelial stem cells 
(LESCs), found at the level of the Vogt palisades. As regards the posterior segment, 
the stem cells used for the treatment of retinal degenerative diseases are embryonic 
stem cells (ESCs), induced pluripotent stem cells (IPSCs), and mesenchymal stem 
cells (MSCs).
LESCs: Also known as corneal epithelial stem cells, they are located in the basal 
epithelial layer of the corneal limbus. They form the border between the cornea and 
the sclera and are implied in the regular corneal renewal. They are also implied in 
corneal repair activity after severe damage of corneal surface.
ESCs: The first ESCs were obtained from mouse embryos and immediately 
showed their ability to express neural markers and to migrate into the retina when 
applied intravitreally. Also, they seemed to be able to integrate into the retinal layers 
and act as neuroprotective factors. Clinical trials conducted in the human eyes 
have demonstrated that the subretinal application of these cells shows no signs of 
rejection, ectopic tissue development, negative proliferation, or tumor formation in 
a 1-year follow-up.
IPSCs: These cells are obtained from reprogramming adult somatic fibroblasts 
through retroviruses or lentiviruses. Compared with ESCs, they show less risk of 
rejection and less need for immunosuppressive therapy. However, further studies 
have suggested that IPSCs can stimulate oncogenes/suppress tumor suppressor 
genes, resulting in gene mutations and malignant transformation. The many 
molecular passages required for their production also seem to act as a trigger for the 
genetic instability shown by these cells.
MSCs: These cells are derived from many different tissues (peripheral blood, 
bone marrow, adipose tissue, cord blood, teeth, central nervous system, and liver). 
Once acquired, MSCs can be expanded in cell cultures maintaining their stemness. 
They can differentiate into various cells (mesodermal, ectodermal, and endodermal 
cells), including neuron-like cells. Since they are capable of secreting neurotrophic 
factors, repairing neural connections, and stimulating the formation of synapses, 
MSCs are also appreciated for their “structural” function. Moreover, they have 
shown a strong immunosuppressive action inhibiting the release of pro-inflamma-
tory cytokines; therefore they allow both autologous and allogenic transplantation. 
Finally, their use does not seem to be related to tumor formation. For these reasons, 
researchers look at stem cells as a promising therapeutic option for degenerative 
retinal diseases. Nevertheless, it must be said that various ocular complications 
related with the use of these cells have been described (see Section 3).
2. Regenerative medicine in the anterior segment of the eye
Stem cells are unspecialized cells that have been a focal point of the field of 
regenerative medicine, frequently considered as the future of medicine. The first 
medical science branch which directly benefits from stem cells for regenerative 
treatment was ophthalmology. The triumph of regenerative medicine in ophthal-
mology can be attributed to its accessibility, ease of follow-up, and the eye being 
an immune-privileged organ. Two key characteristic attributes of stem cells are 
pluripotency, the capacity to differentiate into multiple lineages, and proliferation. 
These cells have the ability to replace damaged or diseased cells under certain spe-
cific circumstances. Stem cell-based therapy has now reached a state where ocular 
tissues damaged by disease or injury can be repaired and/or regenerated. The eye is 
an ideal organ for studying regenerative medicine thanks to the ease of access for 
the therapeutic procedure as well as its status of being an immune-privileged organ. 
Such therapy involves various techniques in which stem cells are injected into both 
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the cellular and extracellular matrix microenvironments. Corneal epithelial stem 
cell transplantation has been the most employed stem cell-based therapy after bone 
marrow transplantation. Stem cell-based treatment in ophthalmology follows two 
possible ways: a cell replacement therapy strategy or a strategy involving trophic 
factor-based guidance cues. Throughout treatment, outcomes are related to differ-
ent factors like our in-depth knowledge of the disease, the source of stem cells, the 
plausible mechanism driving the therapeutic outcome, and the mode of treatment. 
Considering specifically the anterior segment, we will analyze separately stem cell 
pools of the conjunctiva, the cornea, the trabecular meshwork, and the lens. In 
addition we will make few words about the iris stem cell pool. This pool also subspe-
cializes in three types of cells with different capacities for multiplication: putative 
stem cells with high reproductive potential, the generally slow-cycling activity cells, 
and transit amplifying cells (TAC), which have a reduced reproductive potential but 
rapid expansion time.
2.1 Conjunctiva
The conjunctiva, apart from being a protection against pathogenic entry, is 
a connective tissue provided by a high vascularization that offers channels for 
proper flow of nutrients and fluids. From the anatomical point of view, the con-
junctiva is an unkeratinized stratified squamous epithelium, in which goblet cells 
are also present, that covers the exposed scleral surface (bulbar conjunctiva) and 
the interior part of the eyelids (tarsal conjunctiva). Conjunctival cells undertake 
renewal similar to the corneal epithelium, but with a still elusive source of stem 
cells. Conjunctival stem cells undergo a differentiation pathway that can take them 
to become either mucin-producing goblet cells or epithelial cells. The dividing basal 
cell migration starts from the bulbar conjunctiva and takes it to the corneal surface 
before differentiation. Conjunctival epithelial cells are negative for CK3 and CK12 
but positive for CK19. As shown in clonal culture assays, the stem cells located in the 
fornical niche can differentiate into epithelial cells as well as goblet cells. This pro-
vides important evidence that the stem cell pool supporting conjunctival renewal 
is located in the fornix region. Commitment to differentiate into goblet cells occurs 
relatively late; in fact goblet cells are generated by stem cell-derived transient 
amplifying cells. The decision of a conjunctival keratinocyte to differentiate into a 
goblet cell appears to be dependent upon an intrinsic “cell doubling clock.” Ocular 
processes that affect the cornea also affect the conjunctiva; some examples are con-
junctival scarring, cicatricial pemphigoid, thickening, dry eye, or mucin. In order 
to treat conjunctival stem cell deficiency and scarring, conjunctival autografts, oral 
mucous membrane grafts, nasal turbinate mucosa grafts, and amniotic membrane 
are often used. Conjunctival cells cultured on amniotic membrane have been used 
for cell transplantation in patients with limbal stem cell deficiency (LSCD). Recent 
patient follow-up reports have shown that transplantation of autologous conjunc-
tival epithelial cells improved the clinical parameters of total LSCD with respect to 
vision acuity, impression cytology, and in vivo confocal analysis. These cells were 
cultivated ex vivo on amniotic membrane with the presence of epidermal growth 
factor, insulin, cholera toxin, and hydrocortisone to produce the corneal lineage; 
the cells were transplanted after 2 weeks of culture. Ultrathin polymembrane 
substrate has also been shown to support conjunctival epithelial cell proliferation.
2.2 Cornea
The cornea is at the outermost surface of the eye, and its fundamental character-
istic is transparency, which is crucial for vision. It is a clear lens that determines the 
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majority part of the dioptric power of the eye (about 43D). Its normal thickness is 
between 520 and 540 μm and is composed of five layers which are from the outside 
to the inside: corneal epithelium, Bowman’s layer, corneal stroma, Descemet’s mem-
brane, and corneal endothelium. Forty-five million people worldwide are bilaterally 
blind, and another 135 million have a severe impaired vision defect in both eyes 
because of loss of corneal transparency. In order to correct this kind of problems, 
therapies ranging from local medications to corneal transplants, and more recently 
to stem cell therapy, could be applied. The corneal epithelium is a squamous epithe-
lium that has a constant renewal activity, with a vertical turnover of 7–14 days. The 
corneal stem cell pool is located in the limbus, at the periphery of the cornea, and 
these cells are called limbal epithelial stem cells (LESCs). The corneal epithelium 
has a renewal process which is performed by cells generated at the limbus and, 
migrating from there, in opposition to other squamous epithelia in which each stem 
cell has the role of regenerating a limited area of epithelium. In the corneal epithe-
lium, stem cells are located at the corneal periphery in the basal layer of the limbal 
region, called the palisades of Vogt. These are visualized in small clusters and are 
strictly associated with the stromal matrix and the basal membrane, thereby assist-
ing in cell-cell, cell extracellular matrix, and paracrine signaling communication. 
The corneal epithelial basal layer is composed mostly of TAC at various stages of 
maturity, and this could be demonstrated by their elevated expression of a specific 
isoform of the transcription factor p63 along with a high nuclear to cytoplasmic 
ratio. The positivity of ATP-binding cassette subfamily G member 2 (ABCG2) has 
been detected in LESCs as well as in several other cells located in the suprabasal 
region of the limbus, and these markers could be used to identify the LESC pool. 
Some reports also indicate that an RNA binding protein called Musashi-1 can be 
used to stain LESCs. Corneal stem cells also express some other specific markers, 
enolase, cytokeratin (CK)19, and vimentin, but do not express CK3, CK12, or con-
nexin 43, which are present only in mature corneal epithelial cells. Stromal multi-
potent stem cells have been identified and expanded to neurospheres in cultures. 
Corneal stromal stem cells are located in the anterior region of the stroma adjacent 
to the basal side of the palisades of Vogt and were identified as a side population 
using the DNA-binding dye Hoechst 33342. These cells expressed genes encoding 
ABCG2, Bmi1, CD166, c-kit, Pax6, Six2, and Notch1 similarly as mesenchymal 
stem cell and corneal early development markers. Corneal stromal stem cells, when 
differentiated, express keratocyte markers like keratocan, ALDH3A1, CXADR, 
PTDGS, and PDK4. LESC deficiency, either partial or complete, is pathological and 
is caused by either chemical or mechanical injury or thermal burns or acquired by 
diseases like aniridia and Stevens-Johnson syndrome. Treatment of such conditions 
involves LESCs transplantation therapy. In unilateral cases of ocular disease, LESCs 
from the healthy eye are expanded ex vivo for therapeutic purposes using specific 
protocols which involve amniotic membrane or fibrin in the presence or absence of 
growth-arrested 3T3 fibroblast feeder layers. Taking in consideration non-limbal 
cell types, cultured oral mucosal cells and conjunctival epithelial cells have been 
transplanted with success to treat LSCD in humans. The peripheral cornea has been 
proven to contain a higher density of keratocyte precursors with high proliferative 
capacity. Restoration of corneal transparency, stromal thickness, and collagen fibril 
defects have been demonstrated as solvable through the injection of corneal stromal 
stem cells in mice. If it will be shown as successful, such therapy would eliminate 
the shortage of corneas from donors needed for transplantations. Although stem 
cell transplantation is performed worldwide, standardized protocols need to be 
established because of variability in clinical outcomes. An application example of 
LESCs transplant could be in patients with LSCD who are suffering from a severe 
loss of vision and annoying irritation, being also poor candidates for conventional 
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corneal transplant. Hence, new surgical strategies have been devised by transplant-
ing LESCs from an autologous or allogeneic source. When in total LSCD only one 
eye is involved, the reconstruction of the damaged corneal surface can be effectively 
performed by the application of conjunctival limbal autograft. Although conjunc-
tival limbal autograft has high success rates, if transplantation is carried out at the 
acute stage of chemical burns when inflammation remains in “active” stage, the 
surgical outcome is not satisfactory; this notion has been verified in a rabbit model. 
The potential risk to the patient’s donor eye could be reduced with the application 
of different techniques: the first alternative is to perform LESCs allograft, in which 
an allogeneic source of LESCs is derived from either living donors matched with 
HLA or not matching cadavers. Systemic immunosuppression with cyclosporin A or 
other agents is necessary because the donor tissue is allogeneic, but this solution is 
potentially toxic. The success rate of limbal allografts declines with time even with 
systemic application of cyclosporin A. Elements implicated as factors contributing 
to the poor prognosis for keratolimbal allografts are keratinization, severe dry eye, 
chronic inflammation, uncorrected lid, and lid margin abnormalities. A combined 
immunosuppressive regimen together with a meticulous restoration of the ocular 
surface defense has been shown to further improve the long-term visual outcome of 
keratolimbal allografts.
2.3 Trabecular meshwork
The trabecular meshwork is a tissue included between the cornea and the iris 
in the anterior region that has the role of draining the aqueous fluid. It is divided 
into three parts which have their characteristic ultrastructures: inner uveal mesh-
work, corneoscleral meshwork, and juxtacanalicular tissue. Intraocular pressure 
is determined by the correct balance between aqueous production and outflow; 
a malfunction in this mechanism is a possible risk factor for the development of 
glaucoma. Trabecular meshwork cells also are implied in the removal of debris in 
the circulating aqueous humor. Trabecular meshwork cellular markers are vimen-
tin, non-muscle actin, aquaporin-1, acetylated and acetoacetylated alpha-2 adren-
ergic receptor, matrix GLA protein, and chitinase-3-like-1. Recently, the isolation, 
characterization, and specific markers of trabecular meshwork cells have been 
widely studied. These studies suggest that trabecular meshwork cellular popula-
tion has properties similar to stem cells, expressing mesenchymal cell-associated 
markers such as CD73, CD90, and CD105, and they have also the ability to dif-
ferentiate into adipocytes, osteocytes, and chondrocytes. Moreover, further studies 
showed that trabecular meshwork cells with mesenchymal phenotype are isolated 
as a side population or as clones expressing specific stem cell markers, not present 
in mature cells, such as Notch1, OCT-3/OCT-4, ABCG2, AnkG, and MUC1. These 
stem cells have the ability to differentiate into the trabecular meshwork lineage 
expressing CHI3L1, AQP1, and TIMP3 markers that underlies to a phagocytic 
function. Lowering the intraocular pressure is the aim of treatments for glaucoma. 
The idea for this came primarily from the observation that trabecular meshwork 
cell division increased after argon laser trabeculoplasty. Current first-line treat-
ments are topical and oral drugs, argon laser trabeculoplasty, and some surgical 
approaches. Stem cells isolated from human trabecular meshwork and expanded 
in vitro showed evidence of the ability to home to mouse trabecular meshwork and 
differentiate into trabecular meshwork cells in vivo according to recent studies. 
The expanded trabecular meshwork stem cells expressed the stem cell markers 
Notch1, ABCG2, and MUC1 and were expressing also the trabecular meshwork 
marker protein CHI3L1. These trabecular meshwork cells were multipotent and 
had phagocytic properties. Some groups are working on transplanting trabecular 
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meshwork cells or trabecular meshwork progenitor cells combined with argon laser 
trabeculoplasty as a novel cell-based therapy for glaucoma.
2.4 Lens
The lens is composed of the lens capsule, epithelium, and fibers and, like the 
cornea, is transparent. It is hypothesized that lens-specific stem cells reside in 
the lens capsule, although they have not yet been identified. The most confirmed 
hypothesis is that this cell pool comes from the ciliary body, which is anatomically 
close to the lens. It has been demonstrated that lens capsule regeneration occurs in 
lower vertebrates from cells residing in the ciliary body. According to this fact, the 
probability that lens stem cells might reside in the lens capsule is high. Lens pro-
genitor cells have been derived from human ESCs as well as from induced pluripo-
tent stem cells (iPSCs). Lens stem cells are presumed to have a significant role in 
the maintenance of the lens transparency and might be implied in cataractogenesis 
process or other lens abnormalities.
2.5 Iris
The iris has the anatomical role of dividing the space between the cornea and 
lens into anterior and posterior halves. The microscopic structure consists of an 
anterior limiting layer that lines the anterior part of the iris stroma that contains 
muscles, nerves, and vessels and is posteriorly lined by a layer of pigmented 
and non-pigmented cells. The stroma and the vascular structure of the iris take 
embryological origin from the anterior region of the optic cup. Epithelial cells of 
the iris pigment have the ability to grow in spheres and express markers of neural 
stem/progenitor cells such as Msi, Nestin, and Pax6. It has been revealed by studies 
from the mouse iris that these cells can also differentiate both in neuronal and glial 
lineages and express markers such as Rho, Chx10, Otx2, and Olig2. The iris pigment 
epithelial cells have the potential to be used in cell-based therapy, but nevertheless 
not much work on validation and quality assessment has been done. Further studies 
are needed before iris pigment epithelial cells can be used clinically.
3. Regenerative medicine in the posterior segment of the eye
Considering the posterior segment, the main interest is focused on the retina, 
the target of regenerative medicine. Retinal anatomy is quite complex, and focusing 
to the microscopic structure, it can be divided into nine layers of nervous tissue that 
interfaces with the outermost layer of the pigmented epithelium. From external to 
internal, there are inner segment/outer segment layer, external limiting membrane, 
outer nuclear layer, outer plexiform layer, inner nuclear layer, inner plexiform layer, 
ganglion cell layer, nerve fiber layer, and inner limiting membrane.
Stem cells are immature, undifferentiated, highly proliferative cells which are 
capable of self-renewing and differentiating into many cell types [1]. Therefore, 
stem cells represent a potentially endless source of tissue renewal; that is why, in 
the modern era, stem cell therapy has been considered a valid approach for many 
different pathologies. Ophthalmologists and researchers were not slow to guess 
the potential applications of stem cell therapy in various degenerative retinal 
diseases such as retinitis pigmentosa, age-related macular degeneration, Stargardt’s 
macular dystrophy, and other pathological conditions affecting the posterior 
pole of the eye, including retinal vascular occlusions [1, 2]. These pathologies 
are responsible for a progressive decline in visual acuity which, in the case of RP, 
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Stargardt’s disease, and AMD, are due to a constant and irreversible loss of retinal 
photoreceptors and outer nuclear layers. With such premises, it is easy to imagine 
a therapeutic approach based on the use of stem cells to restore the lost retinal 
tissue. Stem cells have shown to be able to perform additional functions, such as 
nutritional support, apoptosis inhibition, synapse formation, immunoregulation, 
and neurotrophin secretion [1] and have increased even more the enthusiasm for 
their application in the ophthalmological field. Furthermore, the use of stem cells 
in the eye seems to offer numerous advantages: firstly, the amount of stem cells 
required is relatively low, which implies lower costs than those required for the 
treatment of other tissues of the human body; secondly, the surgical approach is 
quite easy and the transplanted cells can be easily monitored with the imaging 
methods currently used in clinical practice. Finally, the immune privilege of the eye 
allows avoiding long-term immunosuppressive treatment [1]. Several experimental 
studies conducted on embryonic stem cells (ESCs), induced pluripotent stem cells 
(IPSCs), or mesenchymal stem cells (MSCs) have demonstrated that they tend to 
adapt to the retinal environment and can differentiate not only into photoreceptors 
and RPE cells but also into Müller, amacrine, bipolar, horizontal, and glial cells 
[1]. Retinitis pigmentosa represented one of the first targets of stem cell therapy in 
the ophthalmological area: pioneering animal studies have shown that pluripotent 
stem cells, when placed in murine retinitis pigmentosa models, are able to survive, 
multiplicate, differentiate, organize into, and function as photoreceptor cells, 
developing a retina-like organizational structure [3]; using mouse models, Singh 
et al. have established that at a stage when all host rod cells are lost, transplanted 
rod precursors can lead to the re-establishment of a proper, correctly polarized 
outer nuclear layer, indicating that stem cells may recreate a light-sensitive cell 
layer de novo and restore structurally damaged visual circuits. It has to be said 
that current methods for photoreceptor derivation from human pluripotent stem 
cells require long periods of culture and are often inefficient. Boucherie et al. [4] 
reported that formation of a transient self-organized neuroepithelium from human 
embryonic stem cells cultured together with extracellular matrix can induce a rapid 
conversion into retinal progenitors, which are capable of subsequently differentiat-
ing into photoreceptor precursors in only 10 days and later acquire rod cell identity 
within 4 weeks.
Following such promising results, the first phase I/II clinical trials in humans 
were approved in the United States in 2010; hESC-derived retinal pigment epi-
thelium cells were transplanted into the eyes of patients with Stargardt’s macular 
dystrophy and dry age-related macular degeneration [5]. During differentiation, 
the stem cells “displayed typical RPE behavior and integrated into the host RPE 
layer forming mature quiescent monolayers”[5]; after surgery, structural exams 
showed that cells had attached and persisted during the study. An improvement in 
best corrected visual acuity was reported both in the patient affected by Stargardt’s 
macular dystrophy and in the patient affected by dry AMD. And what is more 
important, in 4 months of follow-up, clinicians did not identify signs of hyperp-
roliferation, abnormal growth, ectopic tissue development, or immune-mediated 
rejection [1, 5], which represent the main concern about stem cell therapy. These 
findings support the safety of ESC-derived stem cells [1, 6].
Since they are autologous, IPSCs (obtained from reprogramming adult somatic 
fibroblast cells using retroviruses or lentiviruses) seem to have an even lower risk 
of rejection. However, because of their abnormal genetic composition, the risk of 
T cell-mediated immune response or oncogenesis should not be underestimated. In 
2015, in fact, a Japanese study on IPSCs that was being conducted on human retinas 
was interrupted because of a new genetic mutation that occurred in the IPSCs of 
one of the patients.
Regenerative Medicine
8
MSCs can differentiate into mesodermal, ectodermal, and endodermal cells 
and can be obtained from many different tissues, including cord and peripheral 
blood, teeth, central nervous system, liver, bone marrow, and adipose tissue [1]. 
Several studies have demonstrated that MSCs can easily turn into neuron-like cells 
and repair damaged cells through a paracrine action which results in a neuropro-
tective function. In rats, subretinal transplant of MSCs led to their differentiation 
into different retinal cell types. These results encouraged clinical trials on humans. 
In a study, Park et al. [2] isolated CD34+ cells from bone marrow and injected it 
intravitreally. They enrolled six patients affected by dry AMD, retinitis pigmen-
tosa, or retinal vascular diseases. Follow-up included serial ophthalmic examina-
tions, perimetry and/or microperimetry, fluorescein angiography, ERG, and 
OCT. After 6 months of follow-up, there was no evidence of worsening neither in 
BCVA nor in full-field ERG. No signs of intraocular inflammation were observed. 
Other studies on MSCs confirmed their safety in terms of hyperproliferation 
and systemic side effects. However, as reported, further MSC applications led to 
other sight-threatening intraocular complications such as elevated intraocular 
pressure, vitreous hemorrhages, tractional and rhegmatogenous retinal detach-
ment, development of preretinal and vitreal fibrous tissue, and shallowing of the 
anterior chamber.
Retinal pigment epithelium replacement represents a promising evolution of 
stem cell therapy. The outer segments of photoreceptors have a very high metabolic 
demand and undergo a daily renewal; in the healthy retina, the apical processes of 
the RPE envelope the outer segments of rods and cones, which contain visual pig-
ment, resulting in a diurnal outer segment recycling. Pathological conditions such 
as drusen deposits, accumulation of lipofuscin, or ischemic insult can result in a dis-
ruption of RPE, slowing photoreceptor metabolism and leading to cellular damage. 
RPE was one of the first tissues to be differentiated in vitro. Nowadays, there are 
many ongoing clinical trials for pluripotent stem cell-derived RPE replacement. The 
success of RPE replacement can be explained by various factors: for a start, RPE cell 
biology and phenotypes are precisely described and conserved among species [7]; 
the differentiation of embryonic stem cells into RPE cells follows default pathways 
that are well characterized; animal models of RPE dysfunction are easily available; 
the amount of RPE required to functionally restore affected retinas is relatively 
small compared with photoreceptors [7]; and the RPE layers within the retina can 
be easily visualized using optical coherence tomography, adaptive optics scanning 
laser ophthalmoscopy, and fundus image. Moreover, studies on animal models 
have established that sheet transplantation is much more beneficial and effective 
than single-cell suspension [7], making retinal patches a fascinating approach to 
degenerative retinal diseases. However, further studies have proven this technique 
unsuccessful in human models. Nevertheless, studies on retinal sheet transplanta-
tion are still ongoing.
Retinal tissue engineering is another intriguing idea for treating late-stage reti-
nal conditions, but various technical and biological issues coming from lab-grown 
neuroretinal tissue design still need to be solved before it can work in clinics. The 
size of 3D retinal tissue derived from human pluripotent stem cells is much smaller 
than that required to obtain a significant clinical outcome, and the implantation 
of a single piece of retinal organoid may not result in an appreciable improvement 
in visual acuity in humans [8]. Because of their plasticity, human pluripotent stem 
cells make an extraordinary source for regenerative medicine. The current chal-
lenges of retinal tissue engineering include establishing reproducible protocols 
for the creation of retinal organoids from stem cells, producing larger pieces of 
retinal tissue from stem cells along with quality supporting biomaterials, improving 
surgical methods of delivering retinal organoids into subretinal space, and finding 
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biomaterials to facilitate the survival and functional integration of hPSC-derived 
grafts into the host’s synaptic environment [8].
In conclusion, pioneering studies conducted on animal models have provided 
hopeful evidence for the hypothesis that stem cell therapy is a valid approach to 
sight-threatening degenerative retinal diseases, including retinitis pigmentosa, 
Stargardt’s disease, dry age-related macular degeneration, and vascular occlusions. 
A number of phase I/II clinical trials on humans seem to have confirmed the effec-
tiveness of this method. We now know for sure that when placed in an appropriate 
tissue niche stem cells not only survive and proliferate but are capable of differ-
entiating into proper retinal cells which exhibit functional characteristics of real 
photoreceptors, resulting in the development of a retina-like structure [9]. Further 
studies are needed to put such promising experimental data into clinical practice 
and establish standardized procedures for the application of stem cell therapy in the 
ophthalmological field.
4. Cell therapy and atrophic retinal diseases: our experience
Visually impaired patients are affected by a series of different neuroretinal 
diseases that can target nerve cells such as ganglion cells (RCG), photoreceptors, or 
support cells such as retinal pigment epithelium cells (RPE). The evolution of these 
pathologies leads to serious impairment of vision. There are many types of retinal 
degenerative diseases, including glaucoma, hereditary retinal dystrophy such as 
retinitis pigmentosa (RP) or Stargardt’s disease, age-related macular degeneration 
(AMD), degenerative myopia, and diabetic retinopathy (DR). In each of these 
pathologies, regardless of its nature, a certain sequence of molecular events gradu-
ally leads to the death of retinal cells.






• Inflammation and para-inflammation [10, 11]
The sequence can begin with oxidation, photooxidation, or photosensitivity. 
This is followed by the release of oxidizing substances and free radicals in the cel-
lular environment which in turn causes lipid peroxidation, oxidation of the critical 
bonds in the protein chains and rupture in those of the DNA, activation of the 
endogenous nuclease, inhibition of the expression of the Bcl2 gene, and priming of 
mechanisms of cell apoptosis.
In physiological conditions, healthy retinal cells possess an arsenal of sub-
stances with protective action, including antioxidant systems (e.g., SOD) and 
enzymes, which serve to balance oxidants and free radicals, minimizing damage. 
One of the best known mechanisms to block or procrastinate apoptotic processes is 
the activation of the Bc12 gene by growth factors, thus avoiding the fate of death, 
regardless of the triggering cause. There are cells such as Müller cells or RPE cells, 
capable of producing, under hypoxic conditions, angiogenic and neurotrophic 
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factors such as FGF and VEGF in order to counterbalance the insult, provided 
that it is transient [12]. In the case of cellular imbalance, for example, for genetic 
or inflammatory reasons, for reduction of the chorioretinal blood flow or when 
a large part of the cells has undergone apoptosis and death with consequent 
induction of a chronic para-inflammatory condition, the trigger of neuroretinal 
pathologies, or their progression, can occur. In our opinion, it is possible to apply 
a therapy aimed at reducing the impact and progression of the disease based on 
these mechanisms. The therapeutic aim is to slow down or prevent the death of 
residual retinal cells [13, 14], highlighting the possible efficacy of cell therapy on 
neurotrophic pathologies of the retina. Currently, in the presence of a dystrophic 
pathology responsible for a low vision condition, the patient can resort to visual 
rehabilitation using magnifying aids or filters to improve contrast. In a smaller 
number of centers, it is possible to benefit from therapies based on the neuro-
modulation of visual signals, in order to improve not only the image on the retina 
but also the perception of the same at the cortical level.
However, the progressive loss of photoreceptors contributes to reducing the per-
formance obtained with visual rehabilitation, and the social impact of the progres-
sive loss of functional autonomy should not be underestimated. New therapeutic 
approaches to neuroretinal degenerations for therapy include restoring defective 
genes, when the disease is caused by a genetic defect, and transplanting stem cells 
to replace or repair defective or dead cells, regardless of the cause [15, 16]. Gene 
therapy is a causal therapy but is currently not clinically available, and the thera-
peutic results obtained experimentally are still marginal in vivo. For this reason, 
the interest of the scientific community is also addressed to stem cell-based repair 
strategies, consisting in the systemic or local injection of stem/progenitor cells for 
the treatment of multiple chronic pathologies [15, 16]. Stem cells are undifferenti-
ated cells that have the ability to self-renew and differentiate into mature cells. On 
this basis, cell replacement therapy has been evaluated in recent years as a viable 
alternative for various pathologies. This therapy hypothesizes the generation of 
retinal cells from stem cells to replace damaged cells in the diseased retina. This goal 
can be achieved by releasing embryonic stem cells (ESCs), induced pluripotent stem 
cells (iPSCs), and mesenchymal stem cells (MSCs) [17] in specific target positions 
of the eye. Stem cell therapy opens up the possibility of replacing or regenerating 
the cells now destroyed during the most common neurodystrophic diseases of the 
retina. However, ESC and iPCS have generated much controversy over ethical, 
immunological, and oncological issues. Instead, the use of MSC appears to be free 
from these concerns. The reparative therapy operated by the implanted cells aims to 
create better conditions for the viability of the residual cells, preventing or slow-
ing their decline. We could therefore define cell therapy, or mediated cell therapy, 
or any therapeutic modality based on the use of cell grafts that aim not only at the 
neuroenhancement of compromised cells and the possible regeneration of some 
elements (such as receptors, mitochondrial components, connection fibers) but also 
to their integration with the above cells. It remains to be asked whether it is easier 
to preserve or promote the survival and function of diseased cells than to actively 
restore retinal cells after they have disappeared following the disease.
4.1 Mesenchymal stem cells as a therapeutic tool
MSCs are characterized by a panel of superficial cell markers proposed by the 
International Society for Cellular Therapy in 2006. The MSC population is defined 
as positive over 95% for CD105, CD73, and CD90 and negative over 95% for CD45, 
CD34, CD14 or CD11b, CD79𝛼 or CD19, and HLA-DR [18]. Some molecules pres-
ent on the surface of MSCs and endothelial cells, such as P-selectin and integrins, 
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let the MSCs themselves migrate to the lesion sites, following their intravascular 
administration. After joining the endothelium, the MSCs are able to cross it in a 
metal-dependent way. MSCs are obtainable from umbilical cord blood, peripheral 
blood, bone marrow, and adipose tissue. MSCs are multipotent: appropriate culture 
conditions associated with specific growth factors drive the differentiation of MSCs 
into specific cell types and can differentiate into various cell types, including osteo-
cytes, adipocytes, vascular endothelial cells, cardiomyocytes, pancreatic beta cells, 
and hepatocytes. Therefore, MSCs play a key role in organogenesis, remodeling, and 
tissue repair. Experimental studies have also reported that MSCs have the potential 
to differentiate into retinal progenitor cells, photoreceptors, and retinal neuron-like 
cells. Furthermore, stem cells, in particular mesenchymal stem cells (MSCs), are 
able to perform multiple functions, such as immunoregulation, anti-apoptosis of 
neurons, and neurotrophin secretion, and the current opinion is that MSCs can 
exert neuroprotective and proregenerative effects, through the secretion of factors 
that act in a paracrine way. An increasing number of studies also report that MSCs 
are capable of giving rise to neuron-like cells. Not only are they able to differentiate 
into neurons for cell replacement therapy but to maintain and regulate the microen-
vironment through paracrine effects by modulating the plasticity of damaged host 
tissues [19, 20].
Of all the MSC collection sites, adipose tissue is particularly interesting and rich 
in stem cells derived from fat, called ADSCs [21]. These cells are able to secrete neu-
rotrophic growth factors and promote survival, restore the release of the synaptic 
transmitter, integrate into existing neural and synaptic networks, and re-establish 
functional connections [22]. ADSCs produce bFGF, vascular endothelial growth 
factor (VEGF), macrophage colony stimulating factor (M-CSF), granulocyte-
macrophage colony stimulating factor (GM-CSF), placental growth factor (PlGF), 
the transforming growth factor (TGFβ), hepatocyte growth factor (HG), insulin 
growth factor (IGF-1), interleukin (IL) and angiogenin, ciliary neurotrophic factor 
(CNTF), and the brain-derived neurotrophic factor (BDNF). Another type of mes-
enchymal tissue is represented by adipose tissue which, just like the bone marrow, 
contains a large population of stem cells within its stromal compartment. Stromal 
adipocytes or fat stromal cells secrete a series of hormones, factors, and protein 
signals, called adipokines, which are associated with the role of the adipocyte in 
energy homeostasis. Fat cells produce the base fibroblast growth factor (bFGF), 
the epidermal growth factor (EGF), the insulin-like growth factor-1 (IGF-1), the 
interleukin (IL), the transforming growth-β (TGFβ), the pigmented epithelium-
derived factor (PEDF), and adiponectin. Another type of cell of mesenchymal 
origin is the platelet, originating from the subdivision of megakaryocytes. Platelets, 
normally known for their hemostatic action, also release substances that promote 
tissue repair, angiogenesis, and inflammation modulation. In addition, they induce 
cell migration and adhesion at angiogenesis sites, as well as the differentiation of 
endothelial progenitors into mature endothelial cells. Platelets produce platelet-
derived growth factor (PDGF), IGF-1, TGFβ, VEGF, bFGF, EGF, platelet-derived 
angiogenesis factor (PDAF), and thrombospondin (TSP) [23].
The therapeutic potential of mesenchymal cells is based on the stabilizing 
effect against the retinal cells exerted by the cytokines and the growth factors 
released paracrinically when they are grafted. The binding of the growth factor 
to the specific surface receptor placed on the cytoplasmic membrane of the target 
cell is the initial step that triggers a cascade of events, activating particular second 
messengers that guarantee the signal transduction at the intracellular level. The 
ultimate goal is the regulation of enzyme activity or gene expression (Figure 1) 
[24, 25]. In particular, activated transcription factors, entering the nucleus and 
binding directly or indirectly to DNA, regulate the expression of various genes with 
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different mechanisms, promoting greater synthesis of proteins including enzymes 
and cytokines. These end products play a key role in cell survival, as assessed by 
the improvement in electrical activity recorded by ERG [27]. The growth factors 
are essential to trigger the cell transition from G0 or resting phase to G1 or growth 
phase. Furthermore these molecules stimulate a wide range of cellular processes, 
including mitosis, cell survival, migration, and cellular differentiation.
4.2 Pathophysiological co-factoriality and cell therapy
The grafting of mesenchymal cells into the suprachoroidal space promotes a 
continuous paracrine increase in GF that can positively interfere with the evolution 
of retinal diseases in several ways.






6. Therapeutic synergy with electrical stimulation (ES)
It is worth noting that the boundaries between these categories are not neces-
sarily defined. The hemorheological activity and its increase help to restore an 
Figure 1. 
The growth factors produced by mesenchymal cells implanted in the suprachoroidal space can act both 
directly on the retinal cells and indirectly, through the mediation of Müller (MC) and RPE cells, generating 
angiotrophic, neurotrophic, anti-inflammatory, and antiapoptotic effects [26, 27]. Image courtesy of P. Limoli-
Milan Low Vision Study Center.
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effective retinal perfusion. Photoreceptor loss that occurs in retinal diseases has 
been identified as the cause of microvascular dysfunction due to the release of 
cellular waste secondary to apoptosis. In fact, there is a correlation between the 
extent of the blood flow and the evolutionary stage of the atrophic pathology, in 
a vicious circle that leads to the final loss of other photoreceptors. Several fac-
tors such as VEGF, bFGF, angiogenin, PDAF, PlGF, PDGF, EGF, and TGF-β have 
been shown to promote endothelial regeneration and therefore can contribute to 
the reperfusion of the choriocapillaris. Furthermore, others, including TSP and 
PEDF, inhibit pathological neovascular processes [28, 29]. Antioxidative activ-
ity prevents oxygen-induced photoreceptor cell death. One of the underlying 
causes of photoreceptor deterioration, which may explain the evolution of retinal 
degeneration, is hyperoxia which results in a more intense oxidation process and 
in the formation of reactive oxygen species (ROS). Excessive generation of reac-
tive oxygen species causes damage to membrane lipoproteins and cellular DNA, 
thus leading to apoptosis and the death of photoreceptors [30]. The mechanism 
involved in hyperoxia can be illuminated by the excessive amount of oxygen in the 
choroid, similar to the arterial oxygen level, which results from the deterioration 
and death of the photoreceptor, in addition to foveal exposure to light and the 
concomitant lack of anti-enzyme oxidants, such as superoxide dismutase (SOD), 
glutathione-peroxidase, and catalases, normally expressed in the mitochondria 
of the internal segments of the cone and capable of catalyzing the decomposition 
of hydrogen peroxide into water and oxygen molecules [31]. The concentration of 
bFGF within photoreceptors has been shown to increase in response to stress in 
order to promote retinal cell survival and prevent oxygen-induced photoreceptor 
cell death [32, 33]. Anti-inflammatory activity can counteract the negative effects 
induced by microglial activation, which occurs as soon as the apoptotic processes 
induced by retinal degeneration begin [34, 35]. In turn, the apoptosis and death of 
photoreceptors are suggested by the ignition of an inflammatory microclimate that 
supports the chronicity and progression of a large number of neurodegenerative 
diseases. In particular, RPE performs a series of essential processes for homeostasis 
and retinal function and constitutes the front of the immune defense of the retina: 
RPE cells are able to secrete a diversified panel of pro-inflammatory cytokines, 
for example, IL-6, IL-8, chemoattractant monocyte protein-1 (MCP-1), and 
interferon-β (IFN-β), as well as anti-inflammatory factors, e.g., IL-11 and TGF-β. 
Intravitreal administration of MSC has been shown to exert a significant effect on 
the host’s immune response by suppressing the production of pro-inflammatory 
cytokines, such as IFN-β and TNF-α through IL-1 receptor antagonist (IL-1RA) and 
prostaglandin E2 receptor (PGE2R) activation [36]. The therapeutic effect of MSCs 
is corroborated by the neurotrophic action of ciliary neurotrophic factor (CNTF) 
and brain-derived neurotrophic factor (BDNF): in culturing retinal ganglion cells, 
under conditions of oxidative stress, MSC expels the last factor that helps reduce 
pro-inflammation cytokine release, e.g., tumor necrosis factor-α (TNF-α) and 
interleukin-1 (IL-1) [33]. M-CSF, GM-CSF, and IL exercise an anti-inflammatory 
function and recruit macrophages by chemotaxis that help remove intraretinal cell 
debris [37]. The antiapoptotic activity is regulated by cytokines with an inhibiting 
(antiapoptotic) or inducing apoptosis (pro-apoptotic) action [38].
Proteins of the Bcl-2 family are particularly known for their regulation of apop-
tosis by interacting with caspases, a family of cysteine-containing protease enzymes 
(proteinases or caspases specific to cysteine’s aspartate). RPE and Müller cells produce 
a wide heterogeneity of factors, e.g., fibroblast growth factors (FGF-1, FGF-2, and 
FGF-5), transforming growth factor-β (TGF-β), insulin-like growth factor 1 (IGF-1), 
ciliary neurotrophic factor (CNTF), platelet-derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF), some members of the Interleukin family, and the 
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pigmented epithelium factor (PEDF). This multitude of growth factors, released in 
the retinal cytosol, is able to produce a wide trophic action on adjacent structures. 
As a consequence, the progressive loss of RPE and Müller cells hinders the incre-
tion of these bioactive agents: their antiapoptotic action is therefore slowed down 
or completely blocked. The administration of mesenchymal cells can interfere with 
the apoptotic process involved in retinal degeneration. The growth factors excreted 
by the grafted mesenchymal cells perform a variety of functions; in particular they 
are able to facilitate the expression of the Bcl-2 gene in order to avoid the inexorable 
death of the cells, regardless of the root causes [17]. The cytoprotective activity of 
the GF contributes to neuroprotection by regulating the metabolic activity of the 
photoreceptors, which is widely compromised in diseases of the retina. Like bFGF, 
PEDF has been found to exert neurotrophic activity, inducing the overall survival of 
photoreceptors [39]. Significant data currently exist to suggest that certain factors 
such as EGF play a role in potentiating the neuroprotective action of Müller cells by 
stimulating their intracellular transcription and bFGF expression [40]. The VEGF 
released by the PRP has been shown to stimulate the proliferation of ADSCs which 
therefore promote the survival of grafted autologous fat and adipocytes [41]. BFGF is 
known to directly promote the survival of photoreceptors [42]. Synergy with electri-
cal stimulation (ES) addresses four main aspects: survival of native cells, survival of 
transplanted cells, integration of transplanted cells, and functional formation of syn-
apses/axon regeneration [43]. In recent years, the synergy between cell therapies and 
electrical stimulation has started to be considered as a possible treatment for degen-
erative diseases. Rat retinas treated with ES showed a reduction in apoptosis [44]. It 
has also been shown that in light-induced retinal degeneration models, stimulation 
with ES contains the death of photoreceptors and preserves the length of the external 
segment [45]. Consequently, it can be assumed that ES treatment can create a more 
balanced and less hostile environment by modifying the secretion of neurotrophic 
factors. ES affects the upregulation of neurotrophic factors in Müller cells normally 
involved in this protection mechanism. After ES, increased expression of in vivo beta 
fibroblast growth factor (b-FGF), insulin growth factor 1 (IGF-1), and brain-derived 
neurotrophic factor (BDNF) was observed. Conversely, ES reduces the production of 
pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β 
(IL-1β), and the pro-apoptotic gene Bax. The release of neurotrophic factors from 
the postsynaptic membrane made possible by neuromodulation, together with the 
enrichment of the same factors in the extracellular environment managed by autolo-
gous grafts, determines the formation of synapses at a presynaptic level, facilitating 
and strengthening neurotransmission [44, 45].
4.3 Cell therapy and routes of administration
The effectiveness of cellular treatments for atrophic pathologies of the retina, 
in order to stabilize and enhance the visual function, is based on two key elements: 
on the one hand, the surgical implant techniques and the cell lines used, and on 
the other by the quantity and quality of residual retinal cells, in other words from 
the earliness of the treatment. The technique must be simple, totally risk-free, and 
painless, and the exploited cells must not cause further damage to the residual reti-
nal cell or to the person. Cytokines and growth factors, released paracrinically from 
the cells administered, must bind to membrane receptors to trigger the pathway of 
intracellular signal transduction. They still require retinal cells that are still alive.
From the studies carried out so far, it seems that the greater the number of 
residual cells, the greater the interaction between GF and chorioretinal cell 
membrane receptors, cellular activity, and, ultimately, the improvement of visual 
performance (VP) [27]. The release of growth factors in a retina with very low 
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cellularity hardly causes detectable neuroenhancement. To achieve this goal, differ-
ent approaches have been explored by inserting these cells in the subtenonian space 
and in the intravitreal or subretinal space. But it seems that positioning the implant 
in the suprachoroidal space can satisfy efficacy and safety. In fact, the graft under 
the tenon, although it has therapeutic significance, does not allow the growth 
factors produced to reach the neuroretinal tissues inside the sclera in important 
quantities.
Intravitreal injections of cellular material are effective and simple to perform, 
but it is necessary to pierce the bulb and leave this material free in the vitreous 
chamber. Serious complications such as infection, vitreoretinal tractions, and 
bleeding are also possible.
The release in the subretinal area seems to be the best for the possibility of a 
potential modification of cell lines due to the direct contact of MSCs with neuronal 
cells, but their grafting is even more dangerous when the retina is compromised by 
atrophic diseases [46]. The suprachoroidal graft maximizes the supply of growth 
factors that flow directly to the choroidal level and through the choroid to the 
entire retina without creating bulbar perforation. In our experience, in order to 
have the therapeutic action of growth factors in the retinal environment, we have 
explored the possibility of treating the dystrophic retina with the implantation of 
the cell types of mesenchymal origin mentioned above, in detail adipose stromal 
cells (ASC), stem cells derived from adipose tissue (ADSC) contained in the 
stromal-vascular fraction (SVF) of adipose tissue, and platelets (PLT) recovered 
in platelet-rich plasma (PRP) [47–49]. To this end, we used a surgical technique 
called Limoli retinal restoration technique (LRRT), described in previous works 
(Figure 2) [27, 50, 51]. The autotransplantation of ADSC, ACS, and PLT above 
the choroid plane improves the incretion of the bioactive factors produced in the 
choroidal flow and, consequently, promotes their widespread diffusion through the 
Figure 2. 
Autotransplantation of adipose tissue, ADSCs from vascular-stromal fraction, and PRP according to the Limoli 
retinal restoration technique (LRRT). The production of growth factors (GF), characteristic of these cells, 
is poured directly into the choroidal flow in paracrine mode, helping to maintain the trophism of the retinal 
cells. The GF, through the choroidal flux, have a direct action on the choroid, on the Müller cells, on the RPE 
cells with improvement of the physiology of the external segments (OS), on the rods, and on the cones. Image 
courtesy of P. Limoli-Milan Low Vision Center.
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retinal tissue, finally exuding in the vitreous body. This action positively influences 
some functional parameters after interaction with the residual cells.
The relapses of cell therapy favor a better choroidal perfusion and a higher 
trophism of the photoreceptors, both directly (GF) and mediated by the RPE and 
Müller cells. It is therefore believed that the interaction between retinal cells and 
growth factors plays a crucial role in leading to an improvement in the prospects of 
degenerative retinopathy, to prevent and/or delay its progression.
The possible goals with cell therapy are schematically:
• Restoration and neuroenhancement on residual cells (Figure 3)
• The partial reduction of the scotoma (Figure 4)
• The improvement of the reading performance by stabilizing the fixation 
obtained with neuroenhancement (Figure 5)
• The improvement of the choroidal flow (Figure 6)
• The conservation of useful areas such as the fovea (when it is still present) or 
the preferential reading field (Figure 7)
• The slowing down of retinal disease (Figure 8)
In our study, greater foveal or retinal thickness is associated with a better prog-
nosis. On the other hand, the lack of cells cannot make interactions between growth 
factors and membrane receptors possible [27, 51]. For this reason, cell therapies 
Figure 3. 
The image shows the effect of a suprachoroidal implantation of autologous mesenchymal cells in a patient with 
retinitis pigmentosa. The wealth of cells in the foveal area, documented by OCT, and therefore the high number 
of interactions between growth factors produced and specific membrane receptors, has allowed (T180) an 
increase in visual performance (BCVA, dB, pts). Image courtesy of P. Limoli-Milan Studies Center.
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must be proposed as soon as the disease starts to progress, when the cells are still 
numerous and the patient realizes the functional change. If a disease is stable and 
its impact on vision is accepted by the patient, it is not advisable to propose cellular 
Figure 4. 
Patient suffering from dry AMD with areolar evolution (retinography top left). The patient treated for 3 
months with supplements did not show any increase in sensitivity even if we recorded a near viscous increase 
(picture below left). After suprachoroid implantation of autologous mesenchymal cells (T30 and T180), we 
observed an increase in sensitivity outside the atrophic area and a further improvement in the visual acuity. 
The near vision passes from 18 points of the initial evaluation to 10 points of the final evaluation which took 
place 9 months later. Image courtesy of P. Limoli-Milan Low Vision Center.
Figure 5. 
The figure shows a case of dry AMD with a small atrophic area. An autologous suprachoroidal implant was 
performed and from the first month (bottom right) an improvement in visual performance was observed in 
terms of sensitivity, electrical activity, and visual acuity for far and near. Retinal neuroenhancement favored 
the re-centering and stabilization of fixations. Image courtesy of P. Limoli-Milan Low Vision Center.
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surgery. Knowledge of the overall amount of retinal cells is of particular impor-
tance: the rehabilitator and surgeon should be aware of this as a precise predictor of 
outcome for patients treated with cell therapy.
5. Conclusions
Stem cell therapy is going to change the natural history of various ophthal-
mologic conditions. For example, several studies have highlighted the chance to 
repair corneal damage through the implantation of conjunctival cells grown on the 
amniotic membrane with a good clinical outcome. In addition, an improvement 
in clinical parameters was observed in patients with limbal stem cell deficiency 
through the implantation of autologous conjunctival stem cells. This is evidenced 
by an increase in the visual acuity and a reduction of irritation. Despite biochemical 
evidences of the existence of stem cell populations in the remaining portions of the 
anterior segment (trabecular, iris, and crystalline), their clinical use is still under 
study.
Pioneering studies conducted on animal models have provided hopeful evi-
dence for the hypothesis that stem cell therapy is a valid approach to sight-threat-
ening degenerative retinal diseases, including retinitis pigmentosa, Stargardt’s 
disease, dry age-related macular degeneration, and vascular occlusions. A number 
of phase I/II clinical trials on humans seem to have confirmed the effectiveness 
Figure 6. 
Patient suffering from dry AMD with a peripheral areolar evolution (blue arrows at the top left). Sensitivity 
appears to be compromised by a paracentral scotoma, but survival of the fovea allows for good visual ability 
(bottom left). After autologous suprachoroidal graft of mesenchymal cells (T180), we observed an increase in 
the thickness of the choroid (top right and center right). Despite the increase in the paracentral scotoma which 
has become more profound as an expression of a now dying area, the improvement of the choroidal circulation 
has contributed to the maintenance of the foveal area and the stabilization of visual performance. Image 
courtesy of P. Limoli-Milan Low Vision Center.
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Figure 7. 
Another case of dry AMD with saving of the foveal area (above) and T0. Six months after LRRT, despite the 
progression of the scotoma within the paracentral atrophic areas, the fovea has maintained its sensitivity, and 
visual performance has been preserved (T180). ERG activity (bottom left) showed an increase (bottom right). 
Image courtesy of P. Limoli-Milan Low Vision Center.
Figure 8. 
Patient with molecular diagnosis of Stargardt’s maculopathy. In 2014, a suprachoroidal graft of autologous 
mesenchymal cells was performed. Visual performance after 5 years appears unchanged. Image courtesy of 
P. Limoli-Milan Low Vision Center.
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of this method. We now know for sure that when placed in an appropriate tissue 
niche stem cells not only survive and proliferate but are capable of differentiating 
into proper retinal cells which exhibit functional characteristics of real photore-
ceptors, resulting in the development of a retina-like structure. Further studies 
are needed to put such promising experimental data into clinical practice and 
establish standardized procedures for the application of stem cell therapy in the 
ophthalmological field.
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